Number | Relative risk | 95%CI lower limit | 95%CI upper limit | p value | |
---|---|---|---|---|---|
Acute GVHD (grades 3–4)a | |||||
Non-rituximab RIC | 647 | 1 | 0.58 | ||
Rituximab-containing RIC | 356 | 0.89 | 0.59 | 1.34 | |
Chronic GVHD | |||||
Non-rituximab RIC | 635 | 1 | 0.51 | ||
Rituximab-containing RIC | 349 | 1.07 | 0..87 | 1.30 | |
Non-relapse mortality | |||||
Non-rituximab RIC | 638 | 1 | 0.14 | ||
Rituximab-containing RIC | 346 | 0.79 | 0.57 | 1.08 | |
Progression/relapse | |||||
Non-rituximab RIC | 638 | 1 | 0.13 | ||
Rituximab-containing RIC | 346 | 0.82 | 0.64 | 1.06 | |
PFS | |||||
Non-rituximab RIC | 638 | 1 | 0.002 | ||
Rituximab-containing RIC | 346 | 0.73 | 0.60 | 0.89 | |
Mortality | |||||
Non-rituximab RIC | 662 | 1 | 0.02 | ||
Rituximab-containing RIC | 358 | 0.76 | 0.60 | 0.96 |